Sign In
Buy TALS
$2.72
+0 (+0%)
At Close: Dec 14, 2023
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
07:00am, Tuesday, 31'st May 2022
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
04:01pm, Tuesday, 17'th May 2022
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
04:01pm, Tuesday, 22'nd Mar 2022
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transfor
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
07:00am, Friday, 11'th Feb 2022
BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 06'th Jan 2022
BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
07:00am, Tuesday, 04'th Jan 2022
BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
07:00am, Monday, 08'th Nov 2021
BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
04:36pm, Thursday, 28'th Oct 2021
BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
04:01pm, Monday, 14'th Jun 2021
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
Talaris Therapeutics Announces Closing of Initial Public Offering
04:01pm, Tuesday, 11'th May 2021
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week
11:29pm, Saturday, 08'th May 2021
Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap.
Talaris Therapeutics Announces Pricing of Initial Public Offering
09:53pm, Thursday, 06'th May 2021
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of
